Iluzanebart

DB18275InvestigationalProtein Based Therapies

Iluzanebart: Overview.

Mechanism
Curator reviewed
Also known as
gamma1 heavy chain Homo sapiens (1-451) [VH (Homo sapiens IGHV5-51*01 (96.9%) -(IGHD) -IGHJ1*01 (100%), CDR-IMGT [8.8.14] (26-33.51-58.97-110)) (1-121) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 CH1 K120, CH3 E12, M14, G1v54-30 CH2 C83, G84.4, C85 (CH1 R · Immunoglobulin G1 [296-cysteine,301-glycine,306-cysteine], anti-(human triggering receptor expressed on myeloid cells 2) (human monoclonal VGL101 γ1-chain), disulfide with human monoclonal VGL101 κ-chain, dimer
Code names
VGL-101

Resolves to

Compound
UNII23Q5AU2MD5CAS2733621-19-5
Targets
Q9NZC2TREM2

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
1Clinical trialPhase, status and sponsor resolved per trial
Sign in
3+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Iluzanebart, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In